# Ionera Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ionera-bio

- Industry: Biotechnology
- Headquarters: Or Yehuda, Israel
- Total disclosed funding: $0.8M
- Latest round: Seed (Feb 1, 2026)
- Investors on record: 1

## About

Based in Isreal, Ionara Bio focused on developing novel, proprietary small-molecule therapeutics targeting the TRPV2 (Transient Receptor Potential Vanilloid 2) ion channel. In Q4 2024, Ionara Bio raised seed funding from investor Peregrine Ventures.

The company develops small-molecule inhibitors of the TRPV2 channel to reduce inflammation driven by macrophages after acute myocardial infarction. Its lead TRPV2 inhibitor aims to preserve cardiac structure and function and limit post-infarction fibrosis.

## Funding rounds

- Seed, Feb 1, 2026, $0.8M — Peregrine Ventures
- Seed, Dec 31, 2024 — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed